Longevity Health Holdings Inc. specializes in creating plasma-based bioactive materials (PBMs) aimed at fostering tissue regeneration and repair in response to injury, illness, and the natural aging process. The company's primary investigational product is CT-101, which acts as a powerful accelerant for bone healing in diverse applications such as tibia fracture recovery, foot/ankle and spinal fusions, serving as a dental bone graft substitute, and filling bone voids. Additionally, CT-101 functions as a tissue healing accelerant, offering potential for treating androgenetic alopecia and persistent chronic wounds. Established in 2008, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Longevity Health Holdings Announces Settlement of Litigation with Puritan Partners LLC
Longevity Health Holdings settled litigation with Puritan Partners LLC that had constrained its access to capital since November 2023.
The resolution involves exchanging existing obligations for $2.35 million in 10% senior secured convertible notes due January 2028.
While the dismissal removes a strategic overhang, the new debt carries a high interest rate and is secured by first-priority liens on substantially all company assets.